PMID- 1908746
OWN - NLM
STAT- MEDLINE
DCOM- 19911003
LR  - 20240426
IS  - 0340-7004 (Print)
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Linking)
VI  - 33
IP  - 6
DP  - 1991
TI  - Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour.
PG  - 389-94
AB  - This study shows that local tumor treatment with low-dose recombinant 
      interleukin-2 (IL-2) can mediate rejection of a large distant solid tumour. When 
      SL2 lymphoma cells were injected intraperitoneally (i.p.) in syngeneic DBA/2 mice 
      on day 0.70% of these mice were cured by daily i.p. injections with 20,000 units 
      IL-2 on days 10-14. After injecting mice with SL2 both i.p. and subcutaneously 
      (s.c.) on the flank. 50% of the mice treated i.p. with low-dose IL-2 rejected 
      both the i.p. tumour and the large distant s.c. tumour. In contrast, i.p. IL-2 
      treatment on days 10-14 cured fewer than 10% of the mice bearing only a s.c. SL2 
      tumour. The described IL-2 immunotherapy also caused systemic tumour rejection in 
      mice bearing both ascitic and solid P815 mastocytoma. Thus it was shown that 
      low-dose IL-2 can induce systemic tumour rejection, when injected at a site of 
      tumour growth. Interleukin-2-induced rejection of s.c. SL2 tumour was highly 
      specific, as mice that were rejecting i.p. and solid s.c. SL2 lymphoma did not 
      reject solid P815 mastocytoma, which was injected s.c. simultaneously on the 
      other flank. Furthermore, solid s.c. tumours consisting of mixtures of SL2 and 
      P815 were not rejected in mice that rejected i.p. SL2 or P815. We conclude that 
      intratumoral injections of low-dose IL-2 can enhance an ongoing weak immune 
      reaction against the tumour resulting in systemic tumour rejection.
FAU - Maas, R A
AU  - Maas RA
AD  - Academisch Ziekenhuis Utrecht, The Netherlands.
FAU - Van Weering, D H
AU  - Van Weering DH
FAU - Dullens, H F
AU  - Dullens HF
FAU - Den Otter, W
AU  - Den Otter W
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Interleukin-2)
SB  - IM
MH  - Animals
MH  - Interleukin-2/*therapeutic use
MH  - Lymphoma, T-Cell/*drug therapy/pathology
MH  - Mast-Cell Sarcoma/*drug therapy/pathology
MH  - Mice
MH  - Mice, Inbred DBA
MH  - Necrosis
PMC - PMC11038110
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
PMCR- 1991/11/01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
PHST- 1991/11/01 00:00 [pmc-release]
AID - BF01741599 [pii]
AID - 10.1007/BF01741599 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 1991;33(6):389-94. doi: 10.1007/BF01741599.